To include your compound in the COVID-19 Resource Center, submit it here.

Oct. 9 Financial Quick Takes: BioNTech, DBV, MiroBio, Hrain, Beijing Gene+, Ginkgo

BioNTech cuts IPO terms
BioNTech AG now plans to sell fewer shares at a lower price range in a move that could shave nearly $1 billion off the biotech’s postmoney valuation. The company’s latest SEC filing for the offering shows it planning to

Read the full 434 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers